INBSINBSHealthcare · Medical Devices

INBS Stock Forecast: Intelligent Bio Solutions, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.39
−7.95% on the day

The median 12-month analyst price target for Intelligent Bio Solutions, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$4.6M
Ticker Nerd rank
21/ 100
Median analyst target
$12
Analysts covering
1
Revenue$1.1M+35.8% y/y
Operating income−$4.0M
Net income−$3.9M
Free cash flow−$3.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−21.0%
1M
−16.8%
YTD
−85.4%
1Y
−78.3%
From 52W high
−92.2%
From 52W low
0.0%
$1
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Intelligent Bio Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
21/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
53
Growth
49
Issuance
33
Accruals
26
Momentum
22
Volatility
18
Value
17
Quality
14

Revisions (53): Analysts have, on balance, been raising their forecasts.

Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

INBS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INBS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Jan 26Apr 26Jul 26Oct 26INBSHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$12
Low
$12
Median
$12
High

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for INBS.

Market Radar

This page is one stock. Monday covers all of them.

INBS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

INBS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Intelligent Bio Solutions, Inc. returned −78.3% against +6.9% for the S&P 500, dividends included.

INBS vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26INBSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INBS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
1.0×

Cheaper than 65% of US stocks

Price / book
0.6×

Cheaper than 83% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
46.8%

Higher than 58% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−225.3%

Higher than 6% of US stocks

Return on assets
−64.7%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Intelligent Bio Solutions, Inc. has a market value of $4.6M and an enterprise value of $239K.

  • Revenue in the twelve months to 30 June 2026: $4.2M. The latest quarter grew 35.8% year on year.

  • Net income over the same four quarters: −$12.5M, a −295.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$12.1M.

  • Shares outstanding: 2.9M.

  • forward P/E: 4.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Intelligent Bio Solutions, Inc. employs 59 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

INBS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
INBSIntelligent Bio Solutions, Inc.$4.6M21
ICCMIceCure Medical Ltd.$4.5M30
WOKWORK Medical Technology Group Ltd.$4.9M16
BMRABiomerica, Inc.$5.0M11
BDMDBaird Medical Investment Holdings Ltd.$5.1M59
POASPhaos Technology Holdings (Cayman) Ltd.$5.1M2
NVNOenVVeno Medical Corp.$3.6M28

Take a look at INBS’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Intelligent Bio Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about INBS

What is the INBS stock price forecast for 2026-2027?

The median 12-month analyst price target for Intelligent Bio Solutions, Inc. is $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INBS stock a buy right now?

Of the 1 analyst covering Intelligent Bio Solutions, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Intelligent Bio Solutions, Inc. 21 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INBS?

As at 21 Nov 2026, Intelligent Bio Solutions, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (53 of 100).

Will INBS stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $12, and Ticker Nerd's factor model ranks Intelligent Bio Solutions, Inc. 21 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INBS stock forecast for 2030?

No analyst covering Intelligent Bio Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INBS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has INBS stock performed over the past year?

Intelligent Bio Solutions, Inc. returned -78.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Intelligent Bio Solutions, Inc. do?

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing and screening solutions. The company’s current offerings center on the Intelligent Fingerprinting platform, which uses fingerprint sweat analysis with a portable handheld reader and single-use cartridge to support drug screening in workplace and other safety-critical settings.

Company

About Intelligent Bio Solutions, Inc.

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing and screening solutions. The company’s current offerings center on the Intelligent Fingerprinting platform, which uses fingerprint sweat analysis with a portable handheld reader and single-use cartridge to support drug screening in workplace and other safety-critical settings. It also develops a biosensor platform aimed at diagnostic and monitoring applications, including clinical chemistry, immunology, hormones, tumor markers, and nucleic acid testing. Intelligent Bio Solutions serves customers across the United States, the United Kingdom, Asia Pacific, and other international markets, positioning itself in the broader medical diagnostics and life sciences sector. Headquartered in New York, the company concentrates on tools that combine portability, speed, and non-invasive sample collection for practical use in professional testing environments.

CEO Mr. Harry Simeonidis · 59 employees · United States · https://ibs.inc